Huang HYMT, Shibata T. Myxofibrosarcoma. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press; 2020. p. 124–6.

Google Scholar 

Sanfilippo R, Miceli R, Grosso F, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18:720–5.

Article  PubMed  Google Scholar 

Iwata S, Yonemoto T, Araki A, et al. Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. J Surg Oncol. 2014;110:707–11.

Article  PubMed  Google Scholar 

Dewan V, Darbyshire A, Sumathi V, Jeys L, Grimer R. Prognostic and survival factors in myxofibrosarcomas. Sarcoma. 2012;2012: 830879.

Article  PubMed  PubMed Central  Google Scholar 

Lee AY, Agaram NP, Qin LX, et al. Optimal percent myxoid component to predict outcome in high-grade myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Ann Surg Oncol. 2016;23:818–25.

Article  PubMed  PubMed Central  Google Scholar 

Look Hong NJ, Hornicek FJ, Raskin KA, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013;20:80–6.

Article  PubMed  Google Scholar 

Mutter RW, Singer S, Zhang Z, Brennan MF, Alektiar KM. The enigma of myxofibrosarcoma of the extremity. Cancer. 2012;118:518–27.

Article  PubMed  Google Scholar 

Emori M, Nakahashi N, Takasawa A, et al. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, SMU-DDCS, harboring an IDH1 mutation. Hum Cell. 2023;36:2195–203.

Article  CAS  PubMed  Google Scholar 

Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25–38.

Article  PubMed  PubMed Central  Google Scholar 

Lucarelli E, De Vita A, Bellotti C, et al. Modeling myxofibrosarcoma: where do we stand and what is missing? Cancers (Basel). 2023;15:5132.

Article  PubMed  PubMed Central  Google Scholar 

Moneo V, Serelde BG, Fominaya J, et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem. 2007;100:339–48.

Article  CAS  PubMed  Google Scholar 

Miserocchi G, De Vita A, Mercatali L, et al. Characterization and drug sensitivity of a new high-grade myxofibrosarcoma cell line. Cells. 2018;7:186.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guerrieri AN, Bellotti C, Penzo M, et al. A novel patient-derived immortalised cell line of myxofibrosarcoma: a tool for preclinical drugs testing and the generation of near-patient models. BMC Cancer. 2023;23:1194.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lohberger B, Stuendl N, Wolf E, Liegl-Atzwanger B, Leithner A, Rinner B. The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity. BMC Cancer. 2013;13:563.

Article  PubMed  PubMed Central  Google Scholar 

Lohberger B, Stuendl N, Leithner A, et al. Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. Sci Rep. 2017;7:44700.

Article  PubMed  PubMed Central  Google Scholar 

Kito F, Oyama R, Sakumoto M, et al. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Hum Cell. 2019;32:214–22.

Article  CAS  PubMed  Google Scholar 

Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Hum Cell. 2021;34:246–53.

Article  CAS  PubMed  Google Scholar 

Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34:1266–73.

Article  CAS  PubMed  Google Scholar 

Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34:1911–8.

Article  CAS  PubMed  Google Scholar 

Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-MFS5-C1: a novel patient-derived cell line of myxofibrosarcoma. Cells. 2022;11:207.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshimatsu Y, Noguchi R, Sin Y, et al. Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2022;35:1993–2001.

Article  CAS  PubMed  Google Scholar 

Kawashima H, Ogose A, Gu W, et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet. 2005;161:28–35.

Article  CAS  PubMed  Google Scholar 

Ariizumi T, Ogose A, Kawashima H, Hotta T, Umezu H, Endo N. Multinucleation followed by an acytokinetic cell division in myxofibrosarcoma with giant cell proliferation. J Exp Clin Cancer Res. 2009;28:44.

Article  PubMed  PubMed Central  Google Scholar 

Salawu A, Fernando M, Hughes D, et al. Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. Br J Cancer. 2016;115:1058–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iwasaki H, Isayama T, Ohjimi Y, et al. Malignant fibrous histiocytoma. A tumor of facultative histiocytes showing mesenchymal differentiation in cultured cell lines. Cancer. 1992;69:437–47.

Article  CAS  PubMed  Google Scholar 

Krause AK, Hinrichs SH, Orndal C, DeBoer J, Neff JR, Bridge JA. Characterization of a human myxoid malignant fibrous histiocytoma cell line, OH931. Cancer Genet Cytogenet. 1997;94:138–43.

Article  CAS  PubMed  Google Scholar 

Kiyozuka Y, Nakagawa H, Uemura Y, et al. Novel cell lines established from a human myxoid malignant fibrous histiocytoma arising in the uterus. Cancer Genet Cytogenet. 2001;127:7–15.

Article  CAS  PubMed  Google Scholar 

Okada T, Lee AY, Qin LX, et al. Integrin-α10 Dependency Identifies RAC and RICTOR as therapeutic targets in high-grade myxofibrosarcoma. Cancer Discov. 2016;6:1148–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li GZ, Okada T, Kim YM, et al. Rb and p53-Deficient Myxofibrosarcoma and undifferentiated pleomorphic sarcoma require Skp2 for survival. Cancer Res. 2020;80:2461–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Vita A, Recine F, Mercatali L, et al. Myxofibrosarcoma primary cultures: molecular and pharmacological profile. Ther Adv Med Oncol. 2017;9:755–67.

Article  PubMed  PubMed Central  Google Scholar 

Piano MA, Brunello A, Cappellesso R, et al. Periostin and Epithelial-Mesenchymal Transition Score as Novel Prognostic Markers for Leiomyosarcoma, Myxofibrosarcoma, and Undifferentiated Pleomorphic Sarcoma. Clin Cancer Res. 2020;26:2921–31.

Article  CAS  PubMed  Google Scholar 

Lohberger B, Bernhart E, Stuendl N, et al. Periplocin mediates TRAIL-induced apoptosis and cell cycle arrest in human myxofibrosarcoma cells via the ERK/p38/JNK pathway. Phytomedicine. 2020;76: 153262.